hh.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis
Department of Medical Rehabilitation, Gällivare Hospital, SE-98282 Gällivare, Sweden.
Department of Medicine/Rehabilitation, Kiruna Hospital, Sweden.
Department of Food and Nutrition, Umeå University, Sweden.
Department of Food and Nutrition, Umeå University, Sweden.ORCID iD: 0000-0002-9291-9342
2006 (English)In: Scandinavian Journal of Rheumatology, ISSN 0300-9742, E-ISSN 1502-7732, Vol. 35, no 5, p. 359-62Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To study the effect of supplementation with omega-3 fatty acids on disease variables and drug consumption in patients with ankylosing spondylitis (AS).

METHODS: Twenty-four patients were randomized to either a low-dose (1.95 g omega-3/day) or a high-dose (4.55 g omega-3/day) supplement. Disease activity, functional impairment, erythrocyte sedimentation rate (ESR), and drug consumption were assessed during visits at baseline and at weeks 7, 14, and 21.

RESULTS: Eighteen patients completed the study, nine patients from each group. The patients in the high-dose group exhibited a significant decrease in disease activity according to the Bath Ankylosing Disease Activity Index (BASDAI; p = 0.038), which was not seen in the low-dose group. Significant differences were not found on drug consumption or in functional capacity in either of the groups. No significant differences were found when comparing the results between the high- and low-dose groups.

CONCLUSION: Omega-3 fatty acids in adequate doses may have the capacity to decrease the disease activity of AS. However, larger and better controlled studies are needed before any further conclusions can be made on the extent of this capacity.

Place, publisher, year, edition, pages
London: Informa Healthcare, 2006. Vol. 35, no 5, p. 359-62
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:hh:diva-20682DOI: 10.1080/03009740600844357ISI: 000241863200006PubMedID: 17062435Scopus ID: 2-s2.0-33750158774OAI: oai:DiVA.org:hh-20682DiVA, id: diva2:586327
Available from: 2013-01-11 Created: 2013-01-11 Last updated: 2017-12-06Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Johansson, Gunnar

Search in DiVA

By author/editor
Johansson, Gunnar
In the same journal
Scandinavian Journal of Rheumatology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 113 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf